deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01718743

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Sponsor: M.D. Anderson Cancer Center

Conditions Hematopoietic Cell Transplantation Recipient Plasma Cell Myeloma
Interventions Ixazomib Citrate Lenalidomide Questionnaire Administration
Updated 16 times since 2017 Last updated: Jan 2, 2025 Started: Dec 3, 2012 Primary completion: Apr 12, 2023 Completion: Apr 12, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hematopoietic Cell Transplantation Recipient and Plasma Cell Myeloma, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 16 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Jan 2024 · 8 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – present · 17 months · monthly snapshot

Change History

16 versions recorded

  1. Feb 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. May 2023 — Jan 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. Sep 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  8. May 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  10. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations